LUCDLucid Diagnostics Inc. stock chart & analysis
Conviction 40HealthcareScan · Mon, Oct 26, 2026Lucid Diagnostics Inc. (LUCD) closed at $0.5089 (+23.82%) on Oct 26, 2026. Its latest daily candle is a bullish belt hold. Price is below its 50-day and below its 200-day moving average. RSI(14) 43, RS Rating 8, -68.8% from its 52-week high, -53.3% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.
Price chart, 63 bars from Wed, Jul 29, 2026 to Mon, Oct 26, 2026. Last close $0.5089, high $1.04, low $0.3030.
Why LUCD moved
From the StockSetups movers recaps that covered LUCD, newest first. A recap states what was known that day.
- Close+23.8%
Lucid Diagnostics closed up 23.8% at $0.51 on 77.6 million shares, about 5.5 times its 20-day average of 14.1 million. Market cap is about $83.6 million.
Top Stock Movers Oct 26, 2026: Why GCTK, CLRO, SGRY Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
LUCD technical analysis
Trend
LUCD is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 33.0% below the 50-day ($0.7601) and 51.0% below the 200-day ($1.04). ADX(14) at 38 points to a strong, established trend. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 43, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 8 puts its weighted 12-month performance ahead of about 8% of the US market.
Volume and volatility
Volume on the latest session ran 7.5× its 20-day average. It trades about $6.3M a day on average. ATR(14) is $0.0760, 14.9% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.08) shows accumulation.
Key levels
The 52-week range is $0.3030 to $1.63; price is 68.8% below the high and 68.0% above the low. The VWAP anchored at the 52-week high is $0.7306, above price.
Performance
LUCD returned +34.8% (1 week), -38.4% (1 month), -44.4% (3 months), -52.0% (6 months), -58.6% (1 year), -53.3% (year to date).
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Surgical & Medical Instruments & Apparatus · Listed 2021 · 82 employees
Recent news
- Tesla Rises 6% as Barclays Upgrade Cites SpaceX Merger Potential; Lucid Drops 4%, Rivian Slips24/7 Wall St. · Mon, Oct 26, 2026
- LCID Stock On Track For Best Week In A Year After Lucid Fires Back At Bankruptcy SpeculationStocktwits · Sat, Oct 24, 2026
- Why Morgan Stanley Believes Lucid Could See Potential Dilution Risk In 2027Stocktwits · Sat, Oct 24, 2026
- Lucid Diagnostics (LUCD) Stock Forum and DiscussionMoomoo · Sat, Oct 24, 2026
- $Lucid Diagnostics (LUCD.US)$Moomoo · Fri, Oct 23, 2026
- Lucid stock faces major risks, but a short squeeze can’t be ruled outInvezz · Fri, Oct 23, 2026
- BTIG reiterates Buy rating on Lucid Diagnostics, $2.50 price targetTradingView · Fri, Oct 23, 2026
- Lucid Diagnostics raises $15 million through Series C preferred stock saleInvesting.com Canada · Thu, Oct 22, 2026
- Form 8K Lucid Diagnostics Inc For: 22 October By Investing.comInvesting.com UK · Thu, Oct 22, 2026
- A 20% annual dividend comes with Lucid Diagnostics (LUCD)'s preferred stock sale.Stock Titan · Thu, Oct 22, 2026
Insider activity
SEC Form 4 transactions in LUCD · open-market 1 buy
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Matheis Dennis Director · Common Stock · 2026-05-20 | Buy | 245K | $245K | 2026-05-20 | 2026-05-21 |
SEC filings
EDGAR filings in LUCD · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.